Press Releases

CAMBRIDGE, Mass. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the Evercore ISI 2 nd Annual HealthCONx Conference on

On track to submit in mid-2020 an investigational new drug application for NTLA-2001 for the treatment of transthyretin amyloidosis Expects to nominate its first T cell receptor-directed engineered cell therapy development candidate for the treatment of acute myeloid leukemia by the end of 2019

CAMBRIDGE, Mass. , Oct. 24, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present third quarter 2019 results and operational highlights in

First reported consecutive in vivo gene knockout and insertion achieves therapeutically relevant results in an alpha-1 antitrypsin deficiency mouse model Inserted highly active WT1-TCR into the endogenous TCR locus for potential improved treatments for hematological and solid malignancies

CAMBRIDGE, Mass. , Oct. 16, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc . (NASDAQ: NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced one oral presentation and four poster

CAMBRIDGE, Mass. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conferences in

Interim Award concluded all technology in dispute was exclusively licensed to Intellia   Parties must negotiate terms and payments to Intellia for Caribou’s use of the chemically modified guide RNAs CAMBRIDGE, Mass. , Sept. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.

NTLA-2001: Intends to submit an investigational new drug application in mid-2020 for lead in vivo program for the treatment of transthyretin amyloidosis On track to nominate first engineered cell therapy development candidate for the treatment of acute myeloid leukemia by end of 2019 Ends quarter

CAMBRIDGE, Mass. , July 30, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present at the following upcoming healthcare conference in

CAMBRIDGE, Mass. , July 25, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present second quarter 2019 results and operational highlights in